Overview
SNX-2112 is a heat shock protein 90 (Hsp90) inhibitor.
Indication
Used for the treatment of schizophrenia .
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2018/12/21 | Phase 4 | Terminated | Sumitomo Pharma (Suzhou) Co., Ltd. | ||
2015/01/12 | Phase 3 | Completed | |||
2012/01/24 | Phase 3 | Completed | Sumitomo Pharma (Suzhou) Co., Ltd. |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Blonanserin Tablets | 国药准字H20244592 | 化学药品 | 片剂 | 7/30/2024 | |
| Blonanserin Tablets | 国药准字HJ20170060 | 化学药品 | 片剂 | 9/18/2021 | |
| Blonanserin Tablets | 国药准字H20223407 | 化学药品 | 片剂 | 6/16/2022 | |
| Blonanserin Tablets | 国药准字H20234039 | 化学药品 | 片剂 | 10/13/2023 | |
| Blonanserin Tablets | 国药准字H20243686 | 化学药品 | 片剂 | 5/15/2024 | |
| Blonanserin Tablets | 国药准字HJ20170287 | 化学药品 | 片剂 | 9/18/2021 | |
| Blonanserin Tablets | 国药准字HJ20170059 | 化学药品 | 片剂 | 9/18/2021 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.